{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T13:10:01Z","timestamp":1765113001792,"version":"3.40.5"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>To evaluate the safety and patient experience of a hospital\u2010initiated home\u2010based iron infusion service in patients with iron deficiency with or without anaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective cohort study, including adult patients who received intravenous iron through a Hospital in The Home service in a single tertiary centre between August 2020 and 2021. A chart review was conducted for documented adverse events (AEs). A telephone survey assessed patient acceptance with three questions on a 5\u2010point Likert scale: (i) How do you perceive the experience of having your infusion given in the home? (ii) Would you like to have the infusion in the same location if you require one in the future? and (iii) Do you feel safe having your infusion at home?<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>Percentage of patients experiencing AEs and patient acceptance of a home\u2010based iron infusion strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred ninety\u2010seven patients were included (181 ferric carboxymaltose and 16 ferric derisomaltose). Six (3%) patients (2 of 181 patients who received ferric carboxymaltose compared with 4 of 16 patients who received ferric derisomaltose, <jats:italic>P<\/jats:italic> &lt;\u20090.001, Fisher's exact) experienced AEs, mostly headache and pruritus. Most patients who participated in the telephone survey had a positive experience (57\/58 (98%)), felt safe (57\/58 (98%)) and preferred future infusions to occur at home (52\/58 (90%)).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A home\u2010based iron infusion strategy was safe and well accepted by patients. Larger studies evaluating the safety profile of different iron formulations in the home setting are required.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.16075","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T09:15:07Z","timestamp":1679303707000},"page":"104-107","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Administration of intravenous iron through a home\u2010based infusion strategy is safe and has high patient acceptance"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-2803","authenticated-orcid":false,"given":"Dorothy","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Northern Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloisa","family":"Atienza","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Santamaria","sequence":"additional","affiliation":[{"name":"Hospital in the Home Service Northern Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabin","family":"Sinnappu","sequence":"additional","affiliation":[{"name":"Hospital in the Home Service Northern Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Health  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000759"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325210"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117383"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26124"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25564"},{"key":"e_1_2_6_8_1","unstructured":"Australian Public Assessment Report for Ferric derisomaltose; 2018. [Ebook]. Retrieved 28 September 2022. Available from URL:https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-ferric_derisomaltose-181105.pdf"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02356.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01156.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01898.x"},{"key":"e_1_2_6_12_1","unstructured":"Cancer Therapy Evaluation Program; 2022. Retrieved 28 August 2022. Available from URL:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15572"},{"key":"e_1_2_6_15_1","unstructured":"Australian Product Information \u2013 Monofer (Ferric Derisomaltose). [Ebook]. Retrieved 28 September 2022. Available from URL:http:\/\/secure.healthlinks.net.au\/content\/pf\/retriever.cfm?product=pfpmonfi10818."},{"key":"e_1_2_6_16_1","unstructured":"Australian Product Information \u2013 Ferrinject (Ferric Carboxymaltose) solution for injection. [Ebook]. Retrieved 28 September 2022. Available from URL:https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-ferric-carboxymaltose-191001-pi.pdf."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13805"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.028"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:16:11Z","timestamp":1706152571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/imj.16075"],"URL":"https:\/\/doi.org\/10.1111\/imj.16075","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"type":"print","value":"1444-0903"},{"type":"electronic","value":"1445-5994"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"2022-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}